Pangaea Oncology

Aug 6, 2024 | aacrjournals.org | Jersey City |Pangaea Oncology

This content is only available via PDF. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License .

Mar 8, 2024 | link.springer.com | Juan Jose |Jose Manuel |Jose Antonio |José Antonio |Pangaea Oncology

AbstractThe prognostic and predictive role of trophoblast cell-surface antigen-2 (Trop-2) overexpression in human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer is currently unknown. We retrospectively analyzed Trop-2 expression and its correlation with clinicopathologic features and pathological complete response (pCR) in HER2-positive early breast cancer (EBC) patients treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab in the PHERGain study.

Jan 24, 2024 | molecular-cancer.biomedcentral.com | Miguel Ángel |Pangaea Oncology

Molecular Cancer volume 23, Article number: 24 (2024) Cite this article Pangaea Oncology has a comprehensive clinical trial portfolio: including investigator initiated trials (IITs) which emphasize Pangaea’s novel scientific development, cooperative academic studies, and industry sponsored trials.

Jul 13, 2023 | molecular-cancer.biomedcentral.com | J. Elizabeth |Pangaea Oncology |Bioinformatics Unit

Patients and tumor samplesThe tumor samples used in the study derived from cancer patients diagnosed between 2015 and 2020 in three hospitals in Barcelona (Spain), Hospital Universitario Dexeus, Hospital de la Santa Creu i Sant Pau and Hospital Clínic de Barcelona. Studies were conducted in accordance with the Declaration of Helsinki, under an approved protocol of the Institutional Review Boards of the three participating hospitals (2020/122-ONC-DEX).